This report is designed for companies and decision-makers seeking actionable insights on market size, growth, trends, and competitive strategies to drive expansion and success in the Arcalyst (rilonacept) industry.
What is the current market size of the arcalyst (rilonacept) industry, and what growth rate is it expected to achieve?
The arcalyst (rilonacept) market size has grown strongly in recent years. It will grow from $221.19 million in 2024 to $239.88 million in 2025 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to increased awareness of autoimmune diseases, increased incidence of cryopyrin-associated periodic syndromes (caps), increased presence of specialty pharmacies, increased awareness of rare diseases, increase in clinical trials and studies for rilonacept.
The arcalyst (rilonacept) market size is expected to see strong growth in the next few years. It will grow to $311.73 million in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to growing demand for injectable biologics, rise in healthcare expenditure, increasing global patient population, rising demand for treatments for inflammatory diseases, rise in demand for personalized medicine. Major trends in the forecast period include advancements in biologic therapies for autoimmune conditions, collaborations between pharmaceutical companies, advances in precision medicine and targeted therapies, technological advancements, innovations in drug delivery systems.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19877&type=smp
What are the major drivers contributing to the growth of the arcalyst (rilonacept) market?
The growing demand for personalized medicines is expected to drive the growth of the arcalyst (rilonacept) market going forward. Personalized medicine is a medical approach that tailors treatment and healthcare decisions to the individual characteristics, such as genetics, environment, and lifestyle, of each patient. The demand for personalized medicine is rising due to its potential to improve treatment effectiveness, reduce adverse effects, and address individual variability in disease progression and drug response. As personalized medicine becomes more common, there is greater awareness and better diagnostic tools available to identify rare and genetically driven conditions. This leads to more people being diagnosed with conditions that Arcalyst can treat, resulting in an increase in demand for the drug. For instance, in February 2024, according to a report published by the Personalized Medicine Coalition (PMC), a US-based non-profit organization, the FDA approved 16 new personalized treatments for rare disease patients in 2023, a notable rise from the six approvals recorded in 2022. Additionally, in February 2023, according to PMC, the FDA approved 12 new personalized medicines in 2022, marking the eighth consecutive year where personalized medicines comprised at least a quarter of all new drug approvals. Therefore, the growing demand for personalized medicines is driving the growth of the arcalyst (rilonacept) market.
What are the major market segments driving the growth of the arcalyst (rilonacept) industry?
The arcalyst (rilonacept) market covered in this report is segmented –
1) By Type: Lyophilized; Liquid
2) By Indication: Cryopyrin-Associated Periodic Syndromes (CAPS); Deficiency Of Interleukin-1 Receptor Antagonist (DIRA); Other Indications
3) By Distribution Channels: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
4) By End User: Adult Patients; Pediatric Patients
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/arcalyst-rilonacept-global-market-report-
What are the key trends shaping the arcalyst (rilonacept) market in the forecast period?
The key trend in the arcalyst (Rilonacept) market is adopting a strategic partnership approach to develop and commercialize Arcalyst with enhanced technology integration and expand market reach. Strategic partnerships involve companies collaborating to utilize each other’s strengths and resources, aiming to achieve shared benefits and mutual success. For instance, in February 2022, Kiniksa Pharmaceuticals Ltd., a Bermuda-based biopharmaceutical company, partnered with Huadong Medicine Co. Ltd., a China-based pharmaceutical company. The partnership focuses on the development and commercialization of Kiniksa’s ARCALYST and mavrilimumab in the Asia-Pacific region. Under the agreement, Kiniksa will receive an upfront payment of $22 million and could earn up to $640 million through development, regulatory, and sales-based milestone payments. Huadong Medicine will hold exclusive rights and take responsibility for developing and commercializing ARCALYST and mavrilimumab in the Asia-Pacific region, including Greater China, South Korea, Australia, and 18 other countries, excluding Japan.
Who are the key market players contributing to the growth of the arcalyst (rilonacept) industry?
Major companies operating in the arcalyst (rilonacept) market include Regeneron Pharmaceuticals Inc., Kiniksa Pharmaceuticals Ltd.
Which regions are leading the growth of the arcalyst (rilonacept) market globally?
North America was the largest region in the arcalyst (rilonacept) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the arcalyst (rilonacept) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Arcalyst (rilonacept) Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19877
Need Customized Data On Arcalyst (rilonacept) Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=19877&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
